Cuproplasia-related gene signature: Prognostic insights for glioma therapy
The identified 19-gene CHRG signature holds promise as a prognostic tool, enabling accurate risk stratification and survival prediction in glioma patients. Integrating this signature with clinical characteristics enhances prognostic accuracy, underscoring its potential clinical utility in optimizing therapeutic strategies and patient care in glioma management.
Authors
- Joseph Descallar (ORCID: https://orcid.org/0000-0002-6919-4865)
- Eng‐Siew Koh (ORCID: https://orcid.org/0000-0002-1664-2513)
- Tyler Shai-Hee (ORCID: https://orcid.org/0000-0001-5442-4384)
- Jessica L. Bell (ORCID: https://orcid.org/0000-0002-8875-0943)
- Toni Rose Jue (ORCID: https://orcid.org/0000-0002-8449-5973)
- Sumanth Nagabushan (ORCID: https://orcid.org/0000-0001-7574-8919)
- Vu Pham (ORCID: https://orcid.org/0000-0002-8884-3584)
- Orazio Vittorio (ORCID: https://orcid.org/0000-0002-6610-1889)
- Riccardo Cazzolli
Institutions
- Liverpool Hospital (AU)
- UNSW Sydney (AU)
- Children's Cancer Institute Australia (AU)
- Sydney Children's Hospital (AU)
- Ingham Institute (AU)
- South Western Sydney Local Health District (AU)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1093/noajnl/vdae233
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00